Clara Blanes-Mira

Clara Blanes-Mira

Auto-generated profile, based on publicly available information

Clara Blanes-Mira

Department of Public Health, History of Science and Gynecology, Universidad Miguel Hernández

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2022 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
NGNicolás S. González-Foutel
Nicolás S. González-Foutel
JGJuliana Glavina
Juliana Glavina
WBWade M. Borcherds
Wade M. Borcherds
MSMatías Safranchik
Matías Safranchik
SBSusana Barrera-Vilarmau
Susana Barrera-Vilarmau
LCLucía B. Chemes
Lucía B. Chemes

25 December 2022 in Molecules
Verified
Journal Article
Open access
PDF file
CBClara Blanes-Mira
Clara Blanes-Mira
PFPilar Fernández-Aguado
Pilar Fernández-Aguado
JAJorge de Andrés-López
Jorge de Andrés-López
Asia Fernandez-CarvajalAsia Fernandez-Carvajal
Asia Fernandez-Carvajal
Antonio Ferrer-MontielAntonio Ferrer-Montiel
Antonio Ferrer-Montiel
GFGregorio Fernandez-Ballester
Gregorio Fernandez-Ballester
The rapid advances of 3D techniques for the structural determination of proteins and the development of numerous computational methods and strategies have led to identifying highly active compounds in computer drug design. Molecular docking is a method widely used in high-throughput virtual screening campaigns to filter potential ligands targeted to proteins. A great variety of docking programs are currently available, which differ in the algorithms and approaches used to predict the binding mode and the affinity of the ligand. All programs heavily rely on scoring functions to accurately predict ligand binding affinity, and despite differences in performance, none of these docking programs is preferable to the others. To overcome this problem, consensus scoring methods improve the outcome of virtual screening by averaging the rank or score of individual molecules obtained from different docking programs. The successful application of consensus docking in high-throughput virtual screening highlights the need to optimize the predictive power of molecular docking methods.

16 May 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
NGNicolas S. Gonzalez-Foutel
Nicolas S. Gonzalez-Foutel
WBWade Borcherds
Wade Borcherds
JGJuliana Glavina
Juliana Glavina
SBSusana Barrera-Vilarmau
Susana Barrera-Vilarmau
ASAmin Sagar
Amin Sagar
LCLucía B. Chemes
Lucía B. Chemes
Many disordered proteins conserve essential functions in the face of extensive sequence variation. This makes it challenging to identify the forces responsible for functional selection. Viruses are robust model systems to investigate functional selection and they take advantage of protein disorder to acquire novel traits. Here, we combine structural and computational biophysics with evolutionary analysis to determine the molecular basis for functional selection in the intrinsically disordered adenovirus early gene 1A (E1A) protein. E1A competes with host factors to bind the retinoblastoma (Rb) protein, triggering early S-phase entry and disrupting normal cellular proliferation. We show that the ability to outcompete host factors depends on the picomolar binding affinity of E1A for Rb, which is driven by two binding motifs tethered by a hypervariable disordered linker. Binding affinity is determined by the spatial dimensions of the linker, which constrain the relative position of the two binding motifs. Despite substantial sequence variation across evolution, the linker dimensions are finely optimized through compensatory changes in amino acid sequence and sequence length, leading to conserved linker dimensions and maximal affinity. We refer to the mechanism that conserves spatial dimensions despite large-scale variations in sequence as conformational buffering. Conformational buffering explains how variable disordered proteins encode functions and could be a general mechanism for functional selection within disordered protein regions.

5 November 2024 in Physiologia Plantarum
Verified
Journal Article
Closed access
ALAdrián Luque
Adrián Luque
CBClara Blanes‐Mira
Clara Blanes‐Mira
LCLara Caballero
Lara Caballero
PMPurificación Martínez-Melgarejo
Purificación Martínez-Melgarejo
MNMiriam Nicolás‐Albujer
Miriam Nicolás‐Albujer
Jose Manuel Perez-PerezJose Manuel Perez-Perez
Jose Manuel Perez-Perez

3 June 2026 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
SCSergio Ortega Del Campo
Sergio Ortega Del Campo
GFGregorio Fernandez-Ballester
Gregorio Fernandez-Ballester
CMClara Blanes Mira
Clara Blanes Mira
VOVíctor Guirado Osorio
Víctor Guirado Osorio
LDLuis Díaz-Martinez
Luis Díaz-Martinez
AGAna Grande-Perez
Ana Grande-Perez
The limited durability of vaccine protection and the rapid emergence of SARS-CoV-2 variants highlight the need for antiviral strategies that extend beyond vaccination and conventional small-molecule inhibitors. Here, we explored a dual approach combining structure-guided peptides predicted to interfere with the viral replication complex with lethal mutagenesis to limit SARS-CoV-2 replication. Using the crystallographic interfaces of nsp10 with nsp14 and nsp16, we designed short inhibitory peptides predicted to interact with the viral proofreading and RNA-capping machinery. In parallel, the mutagenic analog 5-fluorouracil was evaluated to determine its effect on SARS-CoV-2 in Vero E6 cells. Peptides P1 and P6 exhibited potent antiviral activity with minimal cytotoxicity, whereas 5-FU reduced specific infectivity without impairing genome replication. Combined treatment with 5-FU and peptide P1 resulted in >10 4 -fold reduction in infectious virus, achieving near-complete loss of infectivity at non-cytotoxic concentrations. Next-generation sequencing revealed that dual treatment increased mutation frequency, altered mutant spectra, and decreased genome stability, consistent with progression toward error catastrophe. Principal component analysis confirmed that combined treatment generated mutant spectra distinct from either monotherapy. These findings are consistent with a dual antiviral strategy in which structure-guided peptides designed to interact with components of the SARS-CoV-2 replication complex act in combination with lethal mutagenesis to produce a synergistic interaction between these two complementary processes. This integrated approach suggests a potential broad-spectrum antiviral strategy with applicability to other coronaviruses.